TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Adjustable Continence Therapy (ACT) Device for the Treatment of Female Stress Urinary Incontinence

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women~* 18 years or older~* Diagnosed with stress urinary incontinence with or without urethral hypermobility~* Willing to sign informed consent~* Candidates for surgical intervention for stress incontinence~* Negative urinalysis or urine culture within 2 weeks of implantation~* Normal cystourethroscopy~* Failed at least 6 months of previous treatments for stress urinary incontinence (e.g., exercise regimen, electrical stimulation, surgical procedures, etc.)~* May have failed suspension or sling procedures~Exclusion Criteria:~* Pregnant or lactating~* Life expectancy of less than one year~* Insulin dependant diabetic~* Auto-immune disease~* Undergoing radiation therapy~* Active urinary tract infection~* Detrusor instability refractory to meds~* Reduced bladder compliance~* Significant bladder residual \>100mls~* Bladder cancer~* Unsuccessfully treated bladder stones~* Current urethral stricture preventing the passage of a 24 French endoscope~* Neurogenic bladder~* Uncorrected rectocele, cystocele, urethrocele, enterocele or pelvic prolapse of Grade 3 or higher~* Prior pelvic radiotherapy~* Artificial urinary sphincter implanted

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Experimental (Type: EXPERIMENTAL): Open Label Study, ACT (Adjustable Continence Therapy)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female RA patients ≥ 45 years old with self-reported postmenopausal for ≥12 months or prior hysterectomy with bilateral oophorectomy. Female patients ≥ 55 years old who had prior hysterectomy without oophorectomy or with unilateral oophorectomy.~* Having been receiving low to moderate dose of glucocorticoids (prednisone ≤7.5 mg/day or equivalent) for ≥3 months prior to entry. (When taking glucocorticoids PRN, prednisone ≥1mg/day in average.)~* Patients expected to be on glucocorticoid treatment for 3 months after entry.~* Patients with an osteopenic mean lumbar spine (LS; L1-L4) or femoral neck bone mineral density (BMD; -1 \< T-score \< -2.5)~* Patients who provide a written consent of participating in this study.~Exclusion Criteria:~* Patients with condition that may interfere with the evaluation of spinal or hip osteoporosis by DXA such as two or more vertebral (L1-L4) fractures or other vertebral deformity~* Patients with hypercoagulability risk factors or a history of deep vein thrombosis and pulmonary embolism~* History of allergic reactions or intolerance to bazedoxifene or other SERM~* Patients receiving bisphosphonates, parathyroid hormone, SERMs, or anticonvulsants therapies within 6 months prior to entry~* Patients with known bone disorders such as osteomalacia, renal osteodystrophy and hyperparathyroidism~* Patients with undiagnosed uterine bleeding~* Patients with severe renal impairment or creatinine clearance \<30ml/min

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bazedoxifene & Calcium/Vit D (Type: ACTIVE_COMPARATOR): * Enrollment: 57~* Drug: Bazedoxifene 20 mg/day (Viviant)~* Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 \* 2/day)
- Calcium/Vit D (Type: ACTIVE_COMPARATOR): * Enrollment: 57~* Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 \* 2/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Patients willing to participate with confirmed diagnosis of COPD~* 40 years of age or older~* having a 10 pack year smoking history~* able to perform serial pulmonary function tests~* able to use both a Dry powder inhaler (DPI) and Respimat device~Exclusion criteria:~* Significant other disease~* clinically relevant abnormal hematology, chemistry, or urinalysis~* history of asthma~* diagnosis of thyrotoxicosis~* paroxysmal tachycardia related to beta agonists~* history of MI within 1 year, cardiac arrhythmia, hospitalization for heart failure within 1 year~* active tuberculosis, cystic fibrosis, clinically evident bronchiectasis~* significant alcohol or drug abuse~* pulmonary resection~* taking oral beta adrenergics~* taking unstable oral steroids~* daytime oxygen~* enrolled in rehabilitation program~* enrolled in another study or taking investigational products~* pregnant or nursing women, women of child bearing potential not willing to use two methods of birth control~* those who are not willing to comply with pulmonary medication washouts

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Olodaterol (BI1744) Low (Type: EXPERIMENTAL): Low dose inhaled orally once daily from Respimat inhaler
- Olodaterol (BI1744) High (Type: EXPERIMENTAL): High dose inhaled orally once daily from Respimat inhaler
- Tiotropium 18 mcg (Type: ACTIVE_COMPARATOR): 18 mcg inhaled once daily from HandiHaler
- Placebo (Type: PLACEBO_COMPARATOR): Olodaterol placebo and/or Tiotropium placebo inhaled once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Sitagliptin on Endothelial Progenitor Cells

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes;~* Both genders~* Age 40-80~* fasting c-peptide \>=1.0 ng/L~* Therapy with metformin or sulphonylureas~* HbA1c \>7.0%~* No contraindications to sitagliptin use~Exclusion Criteria:~* Type 1 diabetes~* Age \<40 or \>80~* fasting c-peptide \<1.0 ng/L~* Therapy with TZD~* HbA1c \<=7.0%~* Acute concomitant diseases~* Immunological disorders~* Recent (within 3 months) cardiovascular events or surgery~* Pregnancy and lactation~* Inability to provide informed consent

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Sitagliptin 100 mg once daily for 4 weeks
- Control (Type: NO_INTERVENTION): No change in anti-diabetic treatment regimen for at least 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 3 to 70 years.~2. Diagnosis of r/r T-ALL/NK-ALL, T-LBL, or T-NHL (including PTCL-NOS, AITL, ALCL, Extranodal NK/T cell lymphoma).~3. ECOG: 0-2.~4. Life expectancy greater than 12 weeks.~5. Cardiac left ventricle ejection fraction ≥50%.~6. Informed consent explained to, understood by and signed by the patient/guardian. Patient/guardian is given a copy of informed consent.~Exclusion Criteria:~1. Pregnant or lactating.~2. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer detection is not within the normal range; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C Viral (HCV) RNA positive; human immunodeficiency virus (HIV) antibody positive; cytomegalovirus (CMV) DNA positive; syphilis positive.~3. Patients with graft-versus-host disease (GVHD) or who need to use immunosuppressive drugs.~4. Participated in other clinical studies within 2 weeks prior to screening.~5. History of alcoholism, drug abuse or mental illness.~6. Any situations that the investigator believes may increase the risk of patients or interfere with the results of study.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- RD13-01 cell infusion (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) \>/= 27 kg/m2~* HbA1c between 7.5% and 10.5% (inclusive)~* C-Peptide (fasting) greater than or equal to 500 pmol/L~* On stable dose of metformin alone or in combination with a stable dose of sulfonylurea for \>/= 3 months prior to screening, and remain on stable dose throughout the study~* Agree to conduct home-based (fasted) blood glucose testing as directed~Exclusion Criteria:~* Clinically significant abnormalities in medical history or physical exam~* Serum creatinine \> ULN at Screening~* Clinical signs or symptoms of liver disease, acute or chronic hepatitis, or ALT or AST \> 1.5x ULN at Screening~* History of renal transplantation or renal dialysis~* GFR \< 60 mL/min at Screening~* History of diabetic ketoacidosis~* History of greater than 3 episodes of severe hypoglycemia within 6 months of screening~* Allergy to sulfur containing drugs~* Treatment with other drugs or medications not allowed per study specific Disallowed Concomitant Medicines~* Any other significant illness or condition that may interfere with the patient participating or completing the study~* Inability or unwillingness to comply with protocol or study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ISIS-PTP1BRx (Type: EXPERIMENTAL): Weekly Dosing for 26 Weeks
- Placebo (Type: PLACEBO_COMPARATOR): Weekly Dosing for 26 Weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Morning Light Treatment to Improve Glucose Metabolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: 34 subjects (50% female, age 40-65 y)~Subjects will be:~* Prediabetic (HbA1c 5.7% to \<6.5%)~* overweight or obese (BMI\>25 kg/m2)~* be free of moderate to severe obstructive sleep apnea (apnea-hypopnea index\<30).~The laboratory sessions will occur during women's follicular phase or women will be postmenopausal (≥6 months since last menses).~Subjects will be scheduled to participate ≥ 1 month from travel outside the central time zone, and during a time with minimal special events.~Exclusion Criteria:~* Women who are pregnant, planning on becoming pregnant, or are breastfeeding.~* Women on oral contraceptives or hormone replacement therapy will be excluded (alters OGTT and melatonin).~* Men and women who have a child at home that does not sleep through the night will be excluded.~* Adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, and prisoners are also excluded.~* History of any form of diabetes, including use of diabetes medications~* Age outside 35-70 years (we will not enroll anyone older than 70 years because of a reduced response to light).~* Smokers~* Shift workers~* Failed urine drug test (drugs of abuse, nicotine)~* Eye disease/photosensitizing medications~* Sleep medications, diagnosed sleep disorders (history of treatment may affect glucose metabolism),~* Daily beta-blocker, NSAID or melatonin use (confounds DLMO)~* History of psychiatric disorders (confounds effect of light treatment, per relevant items from Mood Disorder, Psychotic Screening and Substance Use Disorders Modules of the Structured Clinical Interview for DSM-IV Axis I Disorders - Non-Patient Edition (SCID-IV/NP) to screen for schizophrenia, bipolar depression, substance abuse, suicidal ideation, obsessive compulsive disorder, PTSD), depressive symptoms using the Center for Epidemiologic Studies - Depression (CES-D) scale~* Irregular menses~* History of cardiovascular disease (excluding hypertension), endocrine, kidney, gastrointestinal or liver disorder, seizures, and cancer.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Bright Light (Type: EXPERIMENTAL): Irradiance is 230 μW/m2 and lux is 500 lux.
- Dim Light (Type: PLACEBO_COMPARATOR): irradiance is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Male or female patient ≥ 18 years of age~* Classification of Sjögren's Syndrome according to ACR/EULAR 2016 criteria (Shiboski et al 2017)~* Seropositive for anti-Ro/SSA antibodies~* Stimulated whole salivary flow rate of ≥ 0.1 mL/min~Inclusion criteria specific for Cohort 1:~* ESSDAI ≥ 5 within the 8 predefined organ domains~* ESSPRI score of ≥5~Inclusion criteria specific for Cohort 2:~* ESSDAI \< 5 within 8 domains scored for inclusion criterion for Cohort 1~* ESSPRI fatigue subscore ≥ 5 or ESSPRI dryness subscore ≥ 5~Exclusion Criteria:~* Sjögren's Syndrome overlap syndromes where another autoimmune rheumatic disease constitutes the principle illness~* Use of other investigational drugs~* Prior use of B cell depleting therapies, abatacept or any other immunosuppressants unless specifically allowed be the protocol.~* Use of steroids at dose \>10 mg/day.~* Uncontrolled ocular rosacea (affecting the eye adnexa), posterior blepharitis or Meibomian gland disease (this criterion applies only to patients considered for Cohort 2)~* Active viral, bacterial or other infections requiring systemic treatment~* Receipt of live/attenuated vaccine within a 2-month period prior to randomization.~* Chronic infection with hepatitis B (HBV) or hepatitis C (HCV).~* Evidence of active tuberculosis (TB) infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 /Arm A (Type: EXPERIMENTAL): CFZ533 dose 1
- Cohort 1/Arm B (Type: EXPERIMENTAL): CFZ533 dose 2
- Cohort 1/Arm C (Type: EXPERIMENTAL): CFZ533 dose 3
- Cohort 1/Arm D (Type: PLACEBO_COMPARATOR): Placebo dose (up to week 24)
- Cohort 1/Arm D1 (Type: EXPERIMENTAL): CFZ533 dose 1 (from week 24)
- Cohort 2/Arm E (Type: EXPERIMENTAL): CFZ533 dose 1
- Cohort 2/Arm F (Type: PLACEBO_COMPARATOR): Placebo dose (up to week 24)
- Cohort 2/Arm F1 (Type: EXPERIMENTAL): CFZ533 dose 2 (from week 24)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Primary open angle glaucoma or ocular hypertension~Exclusion Criteria:~* Patients at risk of progression of visual field loss~* Patients with severe visual field defect~* Patients with any diseases that preclude participation in this study for safety reasons

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DE-117 ophthalmic solution and Latanoprost (Type: OTHER): DE-117 is Experimental. Latanoprost is Active Comparator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin for Treatment of Anemia in Children With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 1-18 years.~2. CKD patients stages 3 to 5 (on or not on dialysis).~3. Baseline hemoglobin 9 - 12 g/dL.~4. Subject should have adequate transferrin saturation (≥20%) and serum ferritin (≥100 ng/mL).~5. Stable erythropoietin therapy for 8 weeks ( defined as a ≤25% change in prescribed dose, no change in the route of administration and no more than one missed or withheld dose).~Exclusion Criteria:~1. Subject scheduled for a living-related kidney transplant.~2. Subject with uncontrolled hypertension.~3. HIV positive patient.~4. The patient with known hematologic disease or cause of anemia other than renal disease.~5. Patient with a history of seizure disorder or received antiepileptic medication for a seizure disorder within 6 months prior to enrolment.~6. Hyperparathyroidism (Intact parathyroid hormone more than 1500 pg/ml or biopsy proven marrow fibrosis).~7. Major surgery within 12 weeks.~8. Active inflammatory disease within 8 weeks of randomization requiring immunosuppressive therapy.~9. Clinical evidence of malignancy.~10. Blood transfusion within 8 weeks prior to initiation of therapy.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Erythropoietin (Type: ACTIVE_COMPARATOR): Recombinant Human Erythropoietin
- Darbepoetin alfa (Type: EXPERIMENTAL): Darbepoetin Alpha

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of T Cell Vaccination in HIV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. CD4 cell counts -from 150 to 450/mm3 and stable for at least 12 months, and treatment with HAART for at least 6 months.~2. Positive cell proliferation assay to CD4 molecule~3. Low HIV viral load (\<400 - 5000 copies/ml) for at least 12 months~4. No change of antiretroviral treatment for at least 6 months~5. Signed informed consent~Exclusion Criteria:~1. Concomitant immunosuppressive or antineoplastic treatment as well as chronic systemic glucocorticoid therapy.~2. Pregnancy and women without any efficacious contraception.~3. Clinically relevant liver disease (AST and/or ALT \>2,5x upper limit of normal range, or total bilirubin \> 3,5 mg/dl).~4. Serum creatinine \>1,8mg/dl or creatinine clearance \<30ml/min.~5. Patients who cannot fully understand the treatment protocol or are unable to sign the informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Vaccination (Type: EXPERIMENTAL): One arm of open label T cell vaccination in which all participants will receive the T cell vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Compound Methyl Salicylate Liniment for Topical Pain: a Multicenter Real-World Study in China

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
The inclusion criteria for the patients were as follows: 1) age 3-75 years, male or female sex; 2) soft tissue pain caused by shoulder and neck pain, back pain, muscle pain, sprain, strain, contusion, muscle swelling and pain, and arthritis; local symptoms included pain, swelling, bruising, or tenderness; 3) signed informed consent and willing to participate in the study.~Patients were excluded if they met the following criteria: 1) allergy to any of the ingredients in this drug; 2) pregnant women, lactating women, and infants aged 0-3 years; 3) the affected area in the eye or mucous membranes, eczema, macules, wounds, and damaged skin; 4) patients without indications for the use of this drug.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete